2012
Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma
Cabrera R, Ararat M, Xu Y, Brusko T, Wasserfall C, Atkinson M, Chang L, Liu C, Nelson D. Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy 2012, 62: 737-746. PMID: 23223899, PMCID: PMC3863727, DOI: 10.1007/s00262-012-1380-8.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsCarcinoma, HepatocellularCase-Control StudiesCD4-Positive T-LymphocytesCoculture TechniquesCytokinesDose-Response Relationship, ImmunologicEnzyme-Linked Immunosorbent AssayHumansInterleukin-2 Receptor alpha SubunitLiver NeoplasmsNiacinamidePhenylurea CompoundsSorafenibT-Lymphocytes, RegulatoryConceptsEffect of sorafenibHepatocellular carcinomaTeff activationT cellsLow dosesTeff responsesTumor immunityRegulatory T cell functionImpact of sorafenibEffector T cellsRegulatory T cellsTreg suppressive functionPeripheral mononuclear cellsCD25 surface expressionT cell functionNovel combination treatmentTreg suppressionEffector CD4Treg functionPharmacologic dosesTeff proliferationImmune reactivitySystemic drugsCD25 expressionMononuclear cells
2011
Survivin inhibition is critical for Bcl‐2 family inhibitor, ABT‐263 to induce apoptosis in liver cancer cells
zhao X, Ogunwobi O, Nelson D, Liu C. Survivin inhibition is critical for Bcl‐2 family inhibitor, ABT‐263 to induce apoptosis in liver cancer cells. The FASEB Journal 2011, 25: 563.13-563.13. DOI: 10.1096/fasebj.25.1_supplement.563.13.Peer-Reviewed Original ResearchYM-155Liver cancer cellsABT-263HCC cellsProtein expressionCancer cellsABT-263 treatmentNormal hepatocytesMechanism of actionHCC cell apoptosisBcl-2 inhibitorsSurvivin protein expressionBcl-2 family inhibitorsHCC managementSignificant apoptotic effectHigh dosesLow dosesSurvivin expressionNovel Bcl-2 inhibitorSurvivin inhibitionSurvivin inhibitorChemotherapeutic alternativesInhibitory effectCell apoptosisSurvivin siRNA
2010
Different radiosensitivity of CD4+CD25+ regulatory T cells and effector T cells to low dose gamma irradiation in vitro
Cao M, Cabrera R, Xu Y, Liu C, Nelson D. Different radiosensitivity of CD4+CD25+ regulatory T cells and effector T cells to low dose gamma irradiation in vitro. International Journal Of Radiation Biology 2010, 87: 71-80. PMID: 20958220, PMCID: PMC3806980, DOI: 10.3109/09553002.2010.518208.Peer-Reviewed Original ResearchMeSH KeywordsAgedApoptosisBcl-2-Associated X ProteinCarcinoma, HepatocellularCaspase 3Cell ProliferationDose-Response Relationship, RadiationFas ReceptorFemaleGamma RaysHumansIn Vitro TechniquesInterferon-gammaInterleukin-10Liver NeoplasmsMaleMiddle AgedRadiation ToleranceT-Lymphocyte SubsetsT-Lymphocytes, RegulatoryConceptsEffector T cellsAdvanced hepatocellular carcinomaRegulatory T cellsT cellsHepatocellular carcinomaLow-dose gamma raysLow-dose irradiationApoptosis-related proteinsImmune responseLow dosesEnhanced immune responseCaspase-3Dose-dependent reductionB-cell lymphoma 2X protein expressionCell lymphoma 2Interleukin-10Peripheral bloodActive caspase-3Low-dose gamma irradiationCytokine secretionTregsLuminex assaysBlood samplesInduction of apoptosis